Omarigliptin(MK-3102) is a DPP-4 inhibitor being developed as a once-weekly treatment for T2D. Its regulatory filing with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) is supported by results from a Phase 3 study of the drug conducted in Japan. The clinical development program for omarigliptin also includes several other late-stage trials that enrolled an estimated 7,500 patients with T2D. Results show that omarigliptin demonstrated comparable efficacy to sitagliptin.